Geron Gets FDA OK to Test Embryonic Stem Cell Therapy on Spinal Cord Injuries

The FDA has removed the hold on Geron’s stem cell trial. Geron plans to commence safety trails of its human embryonic stem cell derived oligodendrocyte progenitors in a small group of patients with recent spinal cord injuries later this quarter.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail